Background and Aims People who have recently injected drugs are a priority population in efforts to achieve hepatitis C
INTRODUCTION
The World Health Organization (WHO) has set a goal to eliminate hepatitis C virus (HCV) as a global public health threat by 2030 [1] . Between 2015 and 2030, WHO targets include reducing new HCV infections by 80%, the number of HCV deaths by 65% and increasing HCV diagnoses from 20 to 90%, and eligible people receiving HCV treatment from < 5 to 80%. People who inject drugs represent a priority population for HCV elimination, given the high prevalence and incidence in this group [2] [3] [4] [5] [6] [7] .
We previously estimated the global, regional and country-level prevalence of HCV (viraemic infections) [8] . In 2015, the global prevalence of HCV infection was estimated to be 1.0% [95% uncertainty interval (UI) = 0.8-1.1], corresponding to 71.1 million (62.5-79.4) people living with HCV [8] . We also estimated the global, regional and country-level HCV antibody prevalence among people with recent injecting drug use (previous 12 months). Among the estimated 15.6 million (UI = 10.2-23.7 million) people with recent injecting drug use aged 15-64 years globally, it is estimated that 52.3% (UI = 42.4-62.1%) are HCV-antibody positive, representing 8.2 million people who have recently injected drugs (UI = 4.7-12.4 million) with past or present HCV [7] . Given that 25% of people clear HCV infection spontaneously [9] , estimates are needed on the prevalence and numbers of people with recent injecting drug use who are living with HCV infection (viraemic infection).
There are no previous estimates at the global, regional and country levels of the HCV RNA (ribonucleic acid) prevalence among people with recent injecting drug use, the number of people with recent injecting drug use who are living with HCV infection (HCV RNA detectable or viraemic) or the proportion of people with recent injecting drug use among all people living with HCV infection. These data are crucial to monitor progress of global HCV elimination efforts and identify high-burden settings to enable appropriate targeting of prevention and treatment strategies to achieve the WHO HCV targets.
The aim of this study was to estimate the global HCV RNA prevalence (viraemic infections) among people who have recently injected drugs; the numbers of people with recent injecting drug use living with HCV infection; and the proportion of people who have recently injected drugs among all people living with HCV at global, regional and country levels.
METHODS

Study design and procedures
This analysis utilized data from two published studies. The first study was a systematic review to estimate the number of people with recent injecting drug use and the HCV antibody (anti-HCV) prevalence among people who have recently (previous 12 months) injected drugs [7] . The second study was a systematic review and modelling study to estimate the global viraemic HCV prevalence [8] .
The first systematic review estimated global, regional and country-level prevalence of injecting drug use among people aged 15-64 years and the prevalence of HIV, HCV and hepatitis B virus (HBV) among people with recent injecting drug use in 2015 [7] . This review was performed consistent with the GATHER (Guidelines for Accurate and Transparent Health Estimates Reporting) and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Multiple search strategies [7] were used to identify papers and reports published since previous reviews of IDU prevalence (from 2008) [10] and of HCV among people who inject drugs (PWID) (from 2011) [2] . Without language restrictions, peer-reviewed databases (MEDLINE, Embase and PsycINFO) and grey literature were searched systematically, and data requests disseminated to international experts and agencies. We searched for data on IDU prevalence and the prevalence of HIV, HCV and HBV among people with recent injecting drug use. Eligible data on prevalence of IDU, HIV antibody, HBsAg and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random-effects meta-analysis. Data on HCV RNA prevalence among people with recent injecting drug use were also extracted. Global, regional and country-level estimates of the HCV antibody (anti-HCV) prevalence among people with recent injecting drug use were used for the current study [7] .
The second systematic review estimated global, regional and country levels of viraemic HCV prevalence in 2015 [8] . Data published between 1 January 2000 and 31 March 2016 were identified through searches of electronic peer-reviewed literature databases, PubMed and Embase [8] . Non-indexed government reports, personal communication with country experts and additional studies identified through manual searches of references noted in publications were included where better data were not available. Papers were scored on the degree to which they could be extrapolated to the general population, the sample size and the year of analysis. A Microsoft Excel-based (version 2007) Markov-type model was populated with the highest-scoring epidemiological data for each country, used to estimate HCV prevalence over time (including in 2015). A Delphi process was used to gain country expert consensus and validate inputs. Further details of data extraction, scoring of data sources, Delphi process and modelling have been published [8] . Global, regional and country-level estimates of the numbers of people with viraemic HCV infection were used for the current study [7] .
Statistical analysis
First, we sought to estimate the prevalence of viraemic HCV infection (detectable HCV RNA) among people with recent injecting drug use at global, regional and country levels. As shown in Table 1 , 48% (98 of 206) of countries had available data on HCV antibody prevalence among people with recent injecting drug use (n = 374 studies) compared to only 9% (19 of 206) of countries with available data on HCV RNA prevalence among people with recent injecting drug use (n = 32 studies). Compared to studies of HCV antibody prevalence among people with recent injecting drug use (n = 374), studies of HCV RNA prevalence among people with recent injecting (n = 32) were less often estimate-grade A (multi-site seroprevalence study with > 1 sample types) (6.3 versus 21.9%) and national samples (6.2% versus 20.6%). Given the poor availability of data on HCV RNA prevalence, we sought to estimate the HCV viraemic proportion (those living with HCV infection) by using estimates of the prevalence of HCV antibodies among people with recent injecting drug use within each country [7] and multiplying by an estimate of the proportion developing viraemic HCV infection [9] . The proportion with viraemic HCV infection among those who were HCV antibody-positive [75%; 95% confidence interval (CI) = 71%, 79%] was estimated using data from a well-characterized merged data set of nine international cohorts of people who had recently injected drugs who had acquired acute HCV infection, and were followed prospectively for spontaneous HCV clearance and viraemic infection [9] . The number of people with recent injecting drug use with viraemic HCV infection was then estimated by multiplying the number of people with recent injecting drug use who were HCV antibody positive by the HCV viraemic prevalence.
Ninety-five per cent UIs were estimated using Monte Carlo simulation taking 100 000 draws. A binomial distribution was used because the parameters of interest were proportions (product of IDU proportion among the population and HCV proportion among PWID). Estimated sample sizes were derived based on the 95% CIs and standard errors of proportion estimates in each country. The simulated UIs incorporated the uncertainty of estimates.
Following the collation of country-specific estimates, estimates of regional and global viraemic HCV infection among people with recent injecting drug use were derived. Region-specific, weighted estimates of the prevalence of HCV were made using all the observed estimates and 95% CI of estimates in each country within that region and deriving a weighted estimate and UI taking into account country population size. Regional estimates were then used to estimate the global prevalence.
The proportion of people with recent injecting drug use among all people living with HCV infection was computed by dividing the total number of people with recent injecting drug use living with HCV by the total number of all people living with HCV for countries where both estimates were available. As above, 95% UIs were simulated taking 100 000 draws carrying forward the standard errors for both people with recent injecting drug use living with HCV and the total HCV viraemic infection prevalence estimates.
RESULTS
Sufficient data were identified to enable estimates of the HCV viraemic prevalence among people with recent injecting drug use in 98 countries, and to estimate the population size of people with recent injecting drug use living with HCV in 76 countries. Sufficient data were identified to enable estimates of the number of people living with HCV overall in 98 countries. There were sufficient data to estimate the number of people with recent injecting drug use as a proportion of all people living with HCV in 55 countries.
Results are shown by region in Table 2 and by country in Table 3 Grading for estimate grade: A = multi-site seroprevalence study with > 1 sample types (e.g. needle-syringe programmes, drug treatment centres, incarcerated IDUs); B1 = seroprevalence study, single sample type and multiple sites; B2 = seroprevalence study, multiple sample types and a single site; C = seroprevalence study, single sample type; D = registration or notification of cases of hepatitis/HIV infection; E = prevalence study using self-reported hepatitis/HIV status; ungraded = estimate with methodology unknown. Table 2 Regional and global estimates of the prevalence of hepatitis C virus (HCV) viraemic infection among people with recent injecting drug use, the number of people with recent injecting drug use living with HCV viraemic infection, the total population living with HCV viraemic infection and the proportion of people with recent injecting drug use among the total population with HCV viraemic infection. 
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At the country level, there was very marked variation in the estimates of HCV viraemic prevalence between countries, ranging from 0.5% (UI = 0.0-1.4; Maldives) to 72.8% (UI = 68.8-76.7; Mauritius) ( Fig. 1 and Table 3 ). The HCV viraemic prevalence was 60-80% in 10 countries, 40-< 60% in 38 countries and < 40% in 50 countries. The largest populations of people with recent injecting drug use living with HCV infection were in Russia (969 500; UI = 463 000-1 570 500), the United States (895 000; UI = 353 500-1 601 500), China (828 000; UI = 493 000-1 228 500) and Brazil (461 000, UI = 336 500-596 500) ( Fig. 2 and Table 3) ; together, these countries accounted for 51% of people with recent injecting drug use living with HCV infection. The top 25 countries accounting for 82% of all people with recent injecting drug use living with HCV infection globally are shown in Fig. 3 . The proportion of people with recent injecting drug use among all people living with HCV infection varied between 0.9% (UI = 0.4-3.0; India) and 46.6% (UI = 22.1-100.0; Commonwealth of Puerto Rico) (Fig. 4 and Table 3 ). The proportion of people with recent injecting drug use among all people living with HCV infection was < 10% in 21 countries, ≥ 10-< 20% in 11 countries and ≥ 20% in 23 countries.
DISCUSSION
This study estimated that there are 6.1 million (UI = 3.4-9.2) people with recent injecting drug use living with HCV infection world-wide, comprising 8.5% (UI = 4.6-13.1) of all HCV infections globally. There was considerable variation in the prevalence of HCV infection among people with recent injecting drug use at regional and country levels, and in the proportion of all HCV infection among people with recent injecting drug use. These findings highlight countries and regions where a focus upon HCV prevention and treatment among people with recent injecting drug use will be required if HCV elimination targets are to be met.
The greatest numbers of people with recent injecting drug use living with HCV infection are in eastern Europe, East and Southeast Asia and North America. Half of all people with recent injecting drug use living with HCV infection are from just four countries: the Russian Federation, the United States, China and Brazil. Further, the top 25 countries account for 82% of all people with recent injecting drug use living with HCV infection globally. Although PWID are a critical population for HCV elimination in many settings, concerted efforts to increase access to prevention and treatment for people with recent injecting drug use in these countries will be pivotal to the success of global HCV elimination efforts. Key among these will be harm reduction measures to prevent incident infections [11] and increased testing, linkage to care and uptake of directly acting anti-viral therapy among people with recent injecting drug use [12, 13] . Countries or territories where it is estimated that at least one-third of people living with HCV infection are people with recent injecting drug use include Georgia, Austria, Finland, Malaysia and Puerto Rico. In a further 16 countries, at least one-quarter of people living with HCV infection are people with recent injecting drug use. However, there are also 21 countries where the proportion of people living with HCVare people with recent injecting drug use is < 10%. Collectively, these data highlight the variation in the proportion of overall viraemic HCV infection occurring among people with recent injecting drug use globally, reflecting the differing epidemiology of HCV in different settings. As such, different types of prevention, testing and treatment strategies will be needed to address HCV elimination targets according to the epidemiology within a given country. It should also be noted that there were 124 countries and territories where injecting drug use is known to occur, but no data were available to assess the proportion of people with HCV infection who are people with recent injecting drug use.
This study was limited to estimates among people with recent injecting drug use and will not include those who have even 'temporarily' or permanently ceased injecting. As such, this study underestimates the proportion of infections that occur among PWID within an overall epidemic, given that some infections due to injecting drug use will be among people with a history of injecting who have ceased injecting. It is critical to consider people who have recently injected drugs as well as those who have ceased injecting in the design of strategies to address HCV.
There are several limitations to this study. The search may have missed some literature (particularly grey literature), despite our wide scope of online searchers and requests for information from people across many countries. To address this possibility, we liaised with the WHO, Global Fund, United Nations Office on Drugs and Crime (UNODC) and Joint United Nations Programme on HIV and AIDS (UNAIDS) staff to contact experts within countries and obtain reports that were not available online. However, we doubt that any missed papers will alter these findings in a meaningful fashion.
Errors may have been made in data extraction and interpretation. To reduce such errors, all sources and data from which the final estimates were derived were doublechecked by at least two reviewers prior to inclusion with a further round prior to finalization with a third reviewer. We have online interactive presentations of these data at (https://ndarc.med.unsw.edu.au/resource/global-epidemiology-injecting-drug-use-2017) to ensure full transparency and to increase the potential for people to interact with the estimates and results, and suggest additional data sources. We encourage feedback at global.reviews@unsw.edu.au.
Although the review team searched for publications in multiple languages, we may have missed documents in languages in which we are not fluent. Those with access to data or papers/reports in other languages should contact us. It is also important to acknowledge a number of features of our approach to synthesis and imputation of estimates, driven by the gaps in data available. Although there has been a clear increase in efforts to quantify the extent of IDU and HCV among PWID, there are still major gaps in data in some regions. A hierarchical grading system was used to evaluate estimates based on geographical generalizability (e.g. from multiple sites) and across various populations of PWID (e.g. treatment and non-treatment samples). Exclusion of estimates based on a study's methodology grade was applied only to estimates of IDU and anti-HCV prevalence. Nonetheless, our recent approach, which involved pooling estimates, and our more sophisticated approach to estimating uncertainty around all our estimates, including our method of estimating uncertainty around imputed estimates, are both improvements upon previous reviews.
A limitation is the lack of country-level data to estimate the viraemic HCV prevalence (98 countries), numbers of people living with HCV (76 countries) and the proportion among the overall population living with HCV among people with recent injecting drug use (55 countries). Data were sparse in regions such as the Caribbean, Latin America, Pacific Island States and Territories, sub-Saharan Africa and the Middle East and North Africa. The estimates for these regions should be interpreted with caution, and highlights that further work is needed to improve estimates in countries from these regions.
In this study, data on HCV antibody prevalence [multiplied by an estimate of the proportion of people with HCV antibodies who would have active viraemia, 0.75 (95% CI = 0.71, 0.79)] was used to estimate the viraemic HCV prevalence, instead of actual data on HCV RNA prevalence. We opted for this approach because the data on HCV antibody prevalence were of higher quality and coverage, and there were few countries for which any data were available for HCV RNA (Table 1) . Instead, we used data on the estimated viraemic prevalence from a well-defined series of nine prospective cohorts of acute HCV infection among people who inject drugs with well-characterized events of spontaneous clearance [9] . Although this provides an extremely accurate estimate of the proportion who progress to viraemic infection, the limitation is that this approach may have either over-or underestimated the true prevalence of viraemic infection in people with recent injecting drug use in various settings. In some regions, increased re-infection risk and/or higher HIV prevalence may result in a higher viraemic prevalence, and our approach may have underestimated the viraemic prevalence [14] . Conversely, it is known that some factors (e.g. female sex) increase spontaneous clearance and can reduce the viraemic prevalence, which might have overestimated the viraemic prevalence observed. Also, these analyses did not take into consideration clearance due to HCV treatment, which might have led to an overestimation of the prevalence and numbers of people with recent injecting drug use living with HCV infection. However, this is also unlikely to have affected these estimates, as uptake of HCV treatment among PWID was very low prior to 2015 [15] [16] [17] [18] [19] . This study clearly demonstrates the need to integrate HCV RNA testing into future studies of HCV among people with recent injecting drug use to enable the evaluation of viraemic HCV RNA prevalence to improve national, regional and global estimates, particularly given that larger numbers of PWID are initiating HCV treatment (and will be anti-HCV positive, but HCV RNA-negative).
Denominator data are also subject to limitations. General population data may be in error for some countries where accurate census data are lacking. Population sizes of people with recent injecting drug use were based on the best available empirical estimates for each country, but there is often considerable uncertainty around estimates of this population, which translates to uncertainty in estimates of the number of PWID with HCV infection and the proportion of HCV infections occurring among people with recent injecting drug use. Estimates of HCV viraemia in people with recent injecting drug use incorporated the uncertainties in the IDU population size, anti-HCV prevalence estimate and viraemia multiplier. However, estimates of the prevalence of recent IDU and of HCV prevalence both in people with recent injecting drug use and in the general population are subject to biases, which may be responsible for some estimates that do not seem correct. Further, the extracted data were often from a single year and changes in injecting drug-user populations and HCV incidence could not be measured. This highlights the importance of continuing to improve country-level estimates of people with recent injecting drug use and those with viraemic HCV infection.
Irrespective of these limitations, this review advances our understanding of HCV prevalence and disease burden among people with recent injecting drug use. Accurate estimates of the prevalence and burden of viraemic HCV infection among people with recent injecting drug use are crucial to guide policy and practice and guide the development of strategies to enhance testing, linkage to care and treatment in this population. This review highlights that concerted efforts will be required in countries with large numbers of people infected with HCV to achieve global HCVelimination among PWID. Further, it highlights that strategies to achieve a reduction in HCV burden will need to be tailored to the individual country, based on the HCV epidemiology and the proportion of overall infections occurring in people with recent injecting drug use. Collectively, these data will inform mathematical modelling to identify strategies to increase diagnosis and treatment and reduce the number of new infections to achieve HCV elimination at a country level. Further work is needed to understand more clearly the population size of people with a history of injecting drug use and the prevalence of viraemic HCV infection and burden in those with former, but not recent, injecting drug use.
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